-+ 0.00%
-+ 0.00%
-+ 0.00%

Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5

Benzinga·03/25/2026 16:24:36
Listen to the news
Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $7 to $5.